New therapies on the horizon for hepatitis C: are we close? Review uri icon

Overview

abstract

  • A myriad of new therapies for treating hepatitis C are in various stages of preclinical and clinical development. As reviewed here, these include nucleic acid-based approaches (antisense and ribozymes), small molecule inhibitors of essential hepatitis C virus (HCV)-encoded enzymes (protease, helicase, and polymerase), immune modulation, and immunotherapy. As more details of the HCV lifecycle are elucidated, new targets and approaches will be discovered. Drug development is difficult, expensive, and always agonizingly slow for patients in need and their physicians. Nonetheless, a broad effort has been mounted for HCV, and substantial progress has been achieved. The prospects for new HCV treatments are bright.

publication date

  • February 1, 2003

Research

keywords

  • Antiviral Agents
  • Hepacivirus
  • Hepatitis C
  • Virus Replication

Identity

Scopus Document Identifier

  • 0037300878

Digital Object Identifier (DOI)

  • 10.1016/s1089-3261(02)00069-7

PubMed ID

  • 12691468

Additional Document Info

volume

  • 7

issue

  • 1